AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA TEMPO Pilot — Pre-Authorization Pathway for Generative AI Medical Devices (2026)

FDA TEMPO Pilot — Pre-Authorization Pathway for Generative AI Medical Devices (2026)

CONCEPT
Rev 2 Nov 1, 2026 01:41 UTC 1 sources

The FDA TEMPO (Total Product Life Cycle Advisory for Modular and Open Devices) pilot program creates a pre-authorization pathway for generative AI medical devices, enabling developers to bring AI-enabled tools to patients before completing full FDA authorization. The pilot represents a regulatory innovation: instead of requiring complete validation before market entry, TEMPO allows conditional authorization with post-market surveillance and iterative validation. This balances innovation speed with safety requirements. Key features include: expedited review for certain AI device categories; conditional authorization with ongoing monitoring; and structured feedback mechanisms between FDA and developers. The program aims to reduce time-to-market for AI medical devices while maintaining safety oversight. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index